Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux

Gut

Volumn 53, Issue 8, 2004, Pages 1070-1074

  Solaymani Dodaran, M ^a   Logan, R F A ^a   West, J ^a   Card, T ^a   Coupland, C ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADULT; AGE; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; COHORT ANALYSIS; COMMUNITY; CONTROLLED STUDY; DATA BASE; ESOPHAGUS CANCER; FEMALE; GASTROESOPHAGEAL REFLUX; GENDER; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; SEX DISTRIBUTION;

EID: 3242658023     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.028076     Document Type: Article

References (42)

1. Spechler SJ, Robbins AH, Rubins HB, et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gostroenterology 1984;87:927-33.
2. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985;313:857-9.
3. Cooper BT, Barbezat GO. Barrett's oesophagus: a clinical study of 52 patients. Q J Med 1987;62:97-108.
4. Achkar E, Carey W. The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. Am J Gastroenterol 1988;83:291-4.
5. Robertson CS, Mayberry JF, Nicholson DA, et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 1988,75:760-3.
6. Hameeteman W, Tytgat GN, Houthoff HJ, et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96(5 Pt 1):1249-56.
7. Ovaska J, Miettinen M, Kivilaakso E. Adenocarcinoma arising in Barrett's esophagus. Dig Dis Sci 1989;34:1336-9.
8. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991;32:1441-6.
9. Wotson RGP, Porter KG, Sloan JM. Incidence of adenocarcinoma in Barrett's oesophagus and an evaluation of endoscopic surveillance. Eur J Gastroenterol Hepatol 1991;3:159-62.
10. Williamson WA, Ellis FH Jr, Gibb SP, et al. Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med 1991;151:2212-16.
11. Bartlesman JF, Hameeteman W, Tytgat GN. Barrett's oesophagus. Eur J Cancer Prev 1992;1:323-5.
12. Iftikhar SY, James PD, Steele RJ, et al. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992;33:1155-8.
13. Moghissi K, Sharpe DA, Pender D. Adenocarcinoma and Barrett's oesophagus. A clinico-pathological study. Eur J Cardiothorac Surg 1993;7:126-31.
14. McDonald ML, Trastek VF, Allen MS, et al. Barretts's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg 1996;111:1135-8.
15. Ortiz A, Martinez de Haro LF, Parrilla P, et al. Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study. Br J Surg 1996;83:274-8.
16. van der Burgh A, Dees J, Hop WC, et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:5-8.
17. Wright TA, Gray MR, Morris AI, et al. Cost effectiveness of detecting Barrett's cancer. Gut 1996;39:574-9.
18. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-15.
19. Ferraris R, Bonelli L, Conio M, et al. Incidence of Barrett's adenocarcinoma in an Italian population: an endoscopic surveillance programme. Gruppo Operativo per lo Studio delle Precancerosi Esofagee (GOSPE). Eur J Gastroenterol Hepatol 1997;9:881-5.
20. Weston AP, Krmpotich PT, Cherian R, et al. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. Am J Gastroenterol 1997;92:407-13.
21. Csendes A, Braghetto I, Burdiles P, et al. Long-term results of classic antireflux surgery in 152 patients with Barrett's esophagus: clinical, radiologic, endoscopic, manometric, and acid reflux test analysis before and late after operation. Surgery 1998;123:645-57.
22. Katz D, Rothstein R, Schned A, et al. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998;93:536-41.
23. Streitz JM jr, Ellis FH jr, Tilden RL, et al. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol 1998;93:911-15.
24. O'Connor JB, Folk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999;94:2037-42.
25. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 1999;94:3413-19.
26. Eckardf VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med 2001;111:33-7.
27. Van der Veen AH, Dees J, Blankensteijn JD, et al. Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut 1989;30:14-18.
28. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
29. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
30. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997;350:1097-9.
31. Lewis JD, Brensinger C, Bilker WB, et al. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2002;11:211-18.
32. ONS. Cancer. London: Office for National Statistics, 1998.
33. Murray L, Watson P, Johnston B, et al. Risk of adenocarcinoma in Barrett's oesophagus: population based study. BMJ 2003;327:534-5.
34. Johnston BT. The significance of heartburn. Q J Med, 2000;93:321-2.
35. Cohen S, Parkman HP. Heartburn - a serious symptom. N Engl J Med 1999;340:878-9.
36. Fass R, Hell RW, Garewal HS, et al. Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut 2001;48:310-13.
37. Armstrong RW, Barman B. Trends in incidence rates of adenocarcinoma of the oesophagus and gastric cardia in New Zealand, 1978-1992. Int J Epidemiol 1996;25:941-7.
38. Batterweck AAM, Schouten LJ, Volovics A, et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000;29:645-54.
39. Brewster DH, Fraser LA, McKinney PA, et al. Socioeconomic status and risk of adenocarcinoma of the oesophagus and cancer of the gastric cardia in Scotland. Br J Cancer 2000;83:387-90.
40. Hansson LE, Sparen P, Nyren O. Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden. Int J Cancer 1993;54:402-7.
41. Hansen S, Wiig JN, Giercksky KE, et al. Esophageal and gastric carcinoma in Norway 1958-1992: incidence time trend variability according to morphological subtypes and organ subsites. Int J Cancer 1997;71:340-4.
42. Launoy G, Faivre J, Pienkowski P, et al. Changing pattern of oesophageal cancer incidence in France. Int J Epidemiol 1994;23:246-51.